Leuven

• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients Recruiting
  2024-512161-14-00 3 2025-01-14 Breast Cancer
• A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During … Recruiting
  2024-511179-13-00 5 2025-01-13 Myotonic Dystrophy type 1 and type 2 (DM1/DM2)
• ZELA trial: Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developi … Recruiting
  2024-513420-41-00 10 2025-01-09 prematurity in neonates
• Myocarditis Therapy with Steroids in patients with a Mildly Reduced ejection fraction (MYTHS-MR) Recruiting
  2022-501547-33-01 11 2024-12-24 Acute myocarditis
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 5 2024-12-20 Relapsed/refractory multiple myeloma in patients who have received 1 t
• A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared … Recruiting
  2023-504022-19-01 5 2024-12-13 Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
• A Phase 3 efficacy and safety study of fosmanogepix for the treatment of adult participants with candidemia and/or invasive candidiasis. Recruiting
  2022-500455-23-00 5 2024-12-11 Candidemia
• A Phase 1/2 Study of VX-670 in Adult Subjects with Myotonic Dystrophy Type 1 Recruiting
  2023-506028-10-00 7 2024-12-11 Myotonic Dystrophy
• A Phase 2 study to Evaluate the Safety, Tolerability and Efficacy of Efgartigimod PH20 SC given by prefilled syringe in Kidney Transplant Re … Recruiting
  2023-508180-72-00 4 2024-12-11 Antibody-Mediated Rejection
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subject … Recruiting
  2024-513860-25-00 9 2024-12-10 Ovarian Neoplasms
• A study to test long-term treatment with brigimadlin in people with solid tumours who took part in a previous study with this medicine Recruiting
  2024-514177-21-00 4 2024-12-02 Solid tumours
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)
• Proactive TDM versus standard use of biologics in psoriasis (HELIOS) Recruiting
  2023-509637-39-00 6 2024-11-28 moderate-to-severe psoriasis
• A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 … Recruiting
  2024-513441-36-00 4 2024-11-27 MMRp/ MSS colon cancer
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308) Recruiting
  2024-511838-12-00 3 2024-11-22 Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can … Recruiting
  2023-509340-10-00 5 2024-10-29 Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
• A Long-term Extension Study of Guselkumab in Pediatric Participants Recruiting
  2023-509560-16-00 5 2024-10-29 Juvenile psoriatic arthritis (jPsA)

Showing 361–384 of 1,135 trials